Evoke Pharma, Inc. (EVOK)
USD 3.09
(6.19%)
USD 3.09
(6.19%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -7.79 Million USD | 4.53% |
| 2022 | -8.16 Million USD | 9.6% |
| 2021 | -9.02 Million USD | 31.92% |
| 2020 | -13.26 Million USD | -86.87% |
| 2019 | -7.09 Million USD | 6.2% |
| 2018 | -7.56 Million USD | 38.13% |
| 2017 | -12.22 Million USD | -13.78% |
| 2016 | -10.74 Million USD | 11.33% |
| 2015 | -12.12 Million USD | 8.5% |
| 2014 | -13.24 Million USD | -367.05% |
| 2013 | -2.83 Million USD | -40.59% |
| 2012 | -2.01 Million USD | 15.98% |
| 2011 | -2.4 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -1.26 Million USD | 19.79% |
| 2024 Q1 | -1.57 Million USD | 20.51% |
| 2023 FY | -7.79 Million USD | 4.53% |
| 2023 Q3 | -1.69 Million USD | 9.32% |
| 2023 Q2 | -1.86 Million USD | 23.89% |
| 2023 Q4 | -1.98 Million USD | -17.33% |
| 2023 Q1 | -2.45 Million USD | -38.61% |
| 2022 FY | -8.16 Million USD | 9.6% |
| 2022 Q2 | -2.22 Million USD | -2.6% |
| 2022 Q1 | -2.17 Million USD | -29.93% |
| 2022 Q3 | -2.01 Million USD | 9.67% |
| 2022 Q4 | -1.77 Million USD | 12.08% |
| 2021 Q3 | -1.96 Million USD | 14.02% |
| 2021 FY | -9.02 Million USD | 31.92% |
| 2021 Q1 | -2.6 Million USD | -14.89% |
| 2021 Q2 | -2.29 Million USD | 12.08% |
| 2021 Q4 | -1.67 Million USD | 15.08% |
| 2020 Q3 | -2.12 Million USD | 69.44% |
| 2020 Q2 | -6.96 Million USD | -289.17% |
| 2020 Q1 | -1.79 Million USD | -26.24% |
| 2020 FY | -13.26 Million USD | -86.87% |
| 2020 Q4 | -2.26 Million USD | -6.52% |
| 2019 Q4 | -1.41 Million USD | 12.89% |
| 2019 Q1 | -1.96 Million USD | -11.62% |
| 2019 Q2 | -2.11 Million USD | -7.57% |
| 2019 Q3 | -1.62 Million USD | 22.99% |
| 2019 FY | -7.09 Million USD | 6.2% |
| 2018 Q4 | -1.76 Million USD | -15.87% |
| 2018 Q3 | -1.51 Million USD | 34.03% |
| 2018 FY | -7.56 Million USD | 38.13% |
| 2018 Q1 | -1.98 Million USD | -542.84% |
| 2018 Q2 | -2.3 Million USD | -16.16% |
| 2017 FY | -12.22 Million USD | -13.78% |
| 2017 Q4 | -308.44 Thousand USD | 94.12% |
| 2017 Q3 | -5.24 Million USD | -222.46% |
| 2017 Q2 | -1.62 Million USD | 67.82% |
| 2017 Q1 | -5.05 Million USD | -230.77% |
| 2016 Q3 | -3.02 Million USD | -1.84% |
| 2016 FY | -10.74 Million USD | 11.33% |
| 2016 Q2 | -2.97 Million USD | 7.9% |
| 2016 Q1 | -3.22 Million USD | -22.91% |
| 2016 Q4 | -1.52 Million USD | 49.51% |
| 2015 Q4 | -2.62 Million USD | 4.07% |
| 2015 Q2 | -3.24 Million USD | 7.94% |
| 2015 Q1 | -3.52 Million USD | -20.58% |
| 2015 Q3 | -2.73 Million USD | 15.6% |
| 2015 FY | -12.12 Million USD | 8.5% |
| 2014 Q2 | -3.54 Million USD | -20.02% |
| 2014 Q3 | -3.82 Million USD | -7.85% |
| 2014 Q4 | -2.91 Million USD | 23.67% |
| 2014 FY | -13.24 Million USD | -367.05% |
| 2014 Q1 | -2.95 Million USD | -82.81% |
| 2013 Q4 | -1.61 Million USD | -232.72% |
| 2013 Q1 | -493.99 Thousand USD | 26.54% |
| 2013 FY | -2.83 Million USD | -40.59% |
| 2013 Q2 | -239.87 Thousand USD | 51.44% |
| 2013 Q3 | -485.9 Thousand USD | -102.57% |
| 2012 FY | -2.01 Million USD | 15.98% |
| 2012 Q1 | -500.15 Thousand USD | 0.0% |
| 2012 Q2 | -358.66 Thousand USD | 28.29% |
| 2012 Q3 | -486.25 Thousand USD | -35.57% |
| 2012 Q4 | -672.45 Thousand USD | -38.29% |
| 2011 FY | -2.4 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -209.24 Million USD | 96.276% |
| Theratechnologies Inc. | -23.95 Million USD | 67.474% |
| Safety Shot Inc | -15.08 Million USD | 48.337% |
| Cosmos Health Inc. | -18.54 Million USD | 57.976% |
| Cronos Group Inc. | -73.96 Million USD | 89.465% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 99.223% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 81.534% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 257.579% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -26.435% |
| ProPhase Labs, Inc. | -16.78 Million USD | 53.568% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -61.164% |
| Dynavax Technologies Corporation | -6.38 Million USD | -21.964% |
| Radius Health, Inc. | -25.79 Million USD | 69.787% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -151.483% |
| Alvotech | -551.73 Million USD | 98.588% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -72.93% |
| Alpha Teknova, Inc. | -36.78 Million USD | 78.814% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 94.421% |
| SCYNEXIS, Inc. | 67.04 Million USD | 111.623% |
| Harrow Health, Inc. | -24.41 Million USD | 68.079% |
| Biofrontera Inc. | -20.13 Million USD | 61.292% |
| DURECT Corporation | -27.62 Million USD | 71.792% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 692.12% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 141.495% |
| OptiNose, Inc. | -35.48 Million USD | 78.039% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 132.582% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | 0.987% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -24.095% |
| SIGA Technologies, Inc. | 68.06 Million USD | 111.448% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 164.866% |
| Shineco, Inc. | -22.44 Million USD | 65.289% |
| Phibro Animal Health Corporation | 2.41 Million USD | 422.529% |
| Procaps Group S.A. | 42.54 Million USD | 118.318% |
| TherapeuticsMD, Inc. | -10.27 Million USD | 24.185% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -81.139% |
| Viatris Inc. | 54.7 Million USD | 114.246% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -72.93% |
| Rockwell Medical, Inc. | -8.43 Million USD | 7.663% |
| Incannex Healthcare Limited | -18.45 Million USD | 57.786% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 50.819% |
| Tilray Brands, Inc. | -244.98 Million USD | 96.819% |
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 116.182% |
| PetIQ, Inc. | 2.13 Million USD | 465.664% |
| Silver Spike Investment Corp. | 7.34 Million USD | 206.16% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 103.121% |
| Journey Medical Corporation | -3.85 Million USD | -102.24% |
| Alimera Sciences, Inc. | -20.13 Million USD | 61.294% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | 4.543% |
| Assertio Holdings, Inc. | -331.94 Million USD | 97.653% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | -18.195% |
| Embecta Corp. | 70.4 Million USD | 111.069% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 61.15% |
| Procaps Group, S.A. | 42.54 Million USD | 118.318% |
| PainReform Ltd. | -9.34 Million USD | 16.606% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 95.138% |
| Hempacco Co., Inc. | -13.12 Million USD | 40.635% |
| Talphera, Inc. | -18.39 Million USD | 57.644% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 118.573% |
| Alvotech | -551.73 Million USD | 98.588% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 102.385% |
| Kamada Ltd. | 8.28 Million USD | 194.064% |
| Indivior PLC | 2 Million USD | 489.615% |
| Currenc Group, Inc. | -15.3 Million USD | 49.092% |
| Flora Growth Corp. | -57.03 Million USD | 86.338% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 61.15% |
| Evolus, Inc. | -61.68 Million USD | 87.368% |
| HUTCHMED (China) Limited | 100.78 Million USD | 107.732% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 105.665% |
| Akanda Corp. | -32.27 Million USD | 75.857% |